secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2024-08-23T23:59:59+00:00
Accession:  0001654954-24-011072
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences appoints new CEO, raises $8M, reduces annual OpEx by $3.1M
------------------------------------------------------------------------------

- New acting CEO Alexander Tokman appointed; CFO Richard Jacroux and Regulatory head Ziad Rouag join.
- Gross proceeds of $8.0M from public offering of common stock and warrants.
- Annualized operating expenses reduced by $3.1M (26%) vs prior year; Q2 OpEx $2.2M.
- Cash and cash equivalents $6.4M at June 30, 2024.
- Advanced FDA regulatory process; initiated new pilot trials at two North American sites.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424011072/0001654954-24-011072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424011072/endra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-011072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer